FDA declines to approve Merck and Eisai's liver cancer combo therapy1 min read . Updated: 08 Jul 2020, 05:26 PM IST
- Due to lack of substantial proof and process, U.S. FDA has denied approval to multiple cancer drugs of several companies
WASHINGTON : July 8 (Reuters) - The U.S. Food and Drug Administration on Wednesday declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima for use in previously untreated patients with liver cancer.
The agency's complete response letter cited lack of sufficient evidence that the combination therapy had a meaningful advantage over available treatments for the condition, the companies said